MAPT and Alzheimer disease: The National Institute on Aging and Alzheimer’s Association (NIA-AA) Research Framework state that Aβ changes, pathologic tau, and neurodegeneration (ATN) comprise the diagnostic standard of AD and highlight the importance of neuroimaging and fluid biomarkers for the accurate diagnosis of AD (Jack et al., 2018).